Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT03650413 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03650413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03650413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 14, 2019
Completion date
July 12, 2022
Enrollment
143 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, ulcerative colitis